| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | B5; B5 receptor; Dendritic cell protein; eIF3m; EIF3M_HUMAN; Eukaryotic translation initiation factor 3 subunit M; Fetal lung protein B5; FLJ29030; GA17; hfl B5; hFL-B5; PCI domain containing 1 (herpesvirus entry mediator); PCI domain-containing protein 1; PCID1; TANGO7 |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | Recombinant Human Eukaryotic translation initiation factor 3 subunit M protein (2-374AA) |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Storage | |
| Target | |
| UniProt # |
Overview
This polyclonal anti-EIF3M antibody raised in Rabbit, tested in ELISA, WB, IHC, IF. Designed to detect EIF3M in Human, Rat for microbiology research.
Key elements and design rationale
- Immunogen: Recombinant Human Eukaryotic translation initiation factor 3 subunit M protein (2-374AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
Biological background
EIF3M (also: B5, B5 receptor, Dendritic cell protein, eIF3m, EIF3M_HUMAN, Eukaryotic translation initiation factor 3 subunit M, Fetal lung protein B5, FLJ29030, GA17, hfl B5, hFL-B5, PCI domain containing 1 (herpesvirus entry mediator), PCI domain-containing protein 1, PCID1, TANGO7) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current EIF3M annotation relevant to microbiology.
Common research applications
- ELISA: Quantify soluble target; ensure samples within the linear detection range.
- WB: Confirms MW, distinguishes isoforms under denaturing conditions.
- IHC: Tissue expression in FFPE/frozen sections; optimize antigen retrieval.
- IF: Subcellular localization in fixed cells/sections; optimize fixation.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human, Rat; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
EIF3M is a protein studied in Human, Rat biology. This polyclonal antibody raised in Rabbit detects EIF3M in ELISA, WB, IHC, IF applications, IgG isotype.
Reported reactive against Human, Rat. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Reported for ELISA, WB, IHC, IF. Optimize dilution/blocking per application. Consult datasheet for working concentrations.
Non-conjugated IgG; requires anti-rabbit-IgG secondary conjugated to your preferred reporter (HRP, AP, fluorophore, or biotin).
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing EIF3M; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
